share_log

12 Health Care Stocks Moving In Friday's After-Market Session

Benzinga ·  Jul 29, 2023 05:32

Gainers

  • Intelligent Bio Solutions (NASDAQ:INBS) stock rose 8.6% to $2.14 during Friday's after-market session. The company's market cap stands at $4.9 million.
  • MSP Recovery (NASDAQ:LIFW) shares increased by 6.68% to $0.23. The company's market cap stands at $76.1 million.
  • Mesoblast (NASDAQ:MESO) stock increased by 5.0% to $4.2. The market value of their outstanding shares is at $683.4 million.
  • Annexon (NASDAQ:ANNX) stock rose 4.98% to $3.37. The market value of their outstanding shares is at $178.8 million.
  • Matinas BioPharma Hldgs (AMEX:MTNB) shares increased by 4.87% to $0.39. The market value of their outstanding shares is at $85.7 million.
  • Renalytix (NASDAQ:RNLX) stock increased by 4.72% to $3.1. The market value of their outstanding shares is at $146.9 million.

Losers

  • OKYO Pharma (NASDAQ:OKYO) shares declined by 29.6% to $1.55 during Friday's after-market session. This security traded at a volume of 249.0K shares come close, making up 245.0% of its average volume over the last 100 days. The company's market cap stands at $39.5 million.
  • Science 37 Hldgs (NASDAQ:SNCE) shares declined by 7.14% to $0.25. The market value of their outstanding shares is at $29.1 million.
  • Impel Pharmaceuticals (NASDAQ:IMPL) stock fell 6.21% to $1.36. The market value of their outstanding shares is at $32.2 million.
  • OptiNose (NASDAQ:OPTN) stock fell 5.99% to $1.1. The company's market cap stands at $123.1 million.
  • eFFECTOR Therapeutics (NASDAQ:EFTR) shares decreased by 5.21% to $0.77. The company's market cap stands at $47.5 million.
  • Navidea Biopharmaceutical (AMEX:NAVB) stock declined by 5.16% to $0.09. Navidea Biopharmaceutical's trading volume hit 2.9 million shares by close, accounting for 40.5% of its average volume over the last 100 days. The market value of their outstanding shares is at $3.1 million. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment